Alessio Fiascarelli

Years Active: 2019-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Elena M Tosca, Elisa Borella, Chiara Piana, Salim Bouchene, Giuseppe Merlino, Alessio Fiascarelli, Paolo Mazzei, Paolo Magni
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. CPT: pharmacometrics & systems pharmacology (2023)
Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Alessandro Bressan, Daniela Bellarosa, Corrado Carrisi, Alessandro Paoli, Mario Bigioni, Patrizia Tunici, Clelia Irrissuto, Massimiliano Salerno, Joaquin Arribas, Elisa de Stanchina, Maurizio Scaltriti, Monica Binaschi
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast cancer research and treatment (2023)
Giuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, Alessandro Bressan, Corrado Carrisi, Daniela Bellarosa, Massimiliano Salerno, Rossana Bugianesi, Rosanna Manno, Cristina Bernadó Morales, Joaquín Arribas, Rachel L Dusek, James E Ackroyd, Phuoc Huy Pham, Rahel Awdew, Dee Aud, Michael Trang, Carmel M Lynch, Jonathan Terrett, Keith E Wilson, Christian Rohlff, Stefano Manzini, Andrea Pellacani, Monica Binaschi
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Molecular cancer therapeutics 18 (9) (2019)

Alessio Fiascarelli.css-eqlu8i{font-size:small;padding-left:4px;}